VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
TWST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
TWSTTwist Bioscience Corporation
$164.60$10.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. TWST
  4. Financial Ratios

Twist Bioscience Corporation (TWST) Financial Ratios

Latest Ratios: P/E Ratio -126.6x · EV/EBITDA N/A · ROE -16.4%. (2016–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

TWST Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$10.2B$1.7B$2.6B$1.2B$1.9B$5.2B$3.0B$656M———
Enterprise Value$10.2B$1.6B$2.5B$960M$1.6B$4.8B$2.9B$617M———
P/E Ratio →-126.62——————————
P/S Ratio27.224.478.384.709.3339.0033.0412.06———
P/B Ratio20.813.565.551.852.418.898.854.31———
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

TWST EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—4.357.923.927.9335.9632.4011.34———
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

TWST Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin50.7%50.7%42.6%36.6%41.4%39.1%31.8%12.8%-26.6%-123.1%-315.2%
Operating Margin-36.2%-36.2%-70.6%-88.6%-115.3%-115.4%-155.5%-200.1%-277.5%-543.2%-1924.0%
Net Profit Margin-20.6%-20.6%-66.7%-83.5%-107.0%-114.9%-155.3%-198.0%-280.2%-550.8%-1943.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-16.4%-16.4%-38.1%-29.0%-31.8%-33.2%-57.3%-70.8%———
ROA-12.4%-12.4%-30.0%-23.5%-26.2%-27.6%-47.8%-71.1%-70.7%-73.2%-57.7%
ROIC-26.9%-26.9%-43.4%-34.8%-51.5%-50.2%-53.6%-72.2%———
ROCE-24.9%-24.9%-35.4%-27.6%-31.1%-30.5%-53.9%-85.7%-81.4%-81.2%-64.4%

TWST Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.290.290.180.150.120.110.110.05———
Debt / EBITDA———————————
Net Debt / Equity—-0.10-0.30-0.31-0.36-0.69-0.17-0.26———
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage——-7177.14-40692.20-2852.43-418.69-176.32-81.98-53.07-64.23-58.10

Net cash position: cash ($183M) exceeds total debt ($137M)

TWST Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.643.644.885.796.588.679.295.285.167.166.80
Quick Ratio3.333.334.545.356.158.168.955.034.846.976.66
Cash Ratio2.542.543.894.595.577.588.054.554.366.566.44
Asset Turnover—0.590.510.320.210.190.230.290.220.130.03
Inventory Turnover6.566.567.464.853.042.545.006.475.3413.157.67
Days Sales Outstanding—55.5640.7065.6272.2578.74103.0081.2377.7979.53116.30

TWST Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.2%0.4%0.4%0.2%0.1%0.0%———
Total Shareholder Yield0.0%0.0%0.2%0.4%0.4%0.2%0.1%0.0%———
Shares Outstanding—$60M$58M$57M$54M$48M$39M$27M$27M$19M$19M

Key Metrics

Growth RegimeAccelerating
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent operating losses and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Margin Expansion Stalls at 52%

Gross margin improved to 52.8% in 2026Q3 from 41.0% in 2024Q2, as reported in financial statements, but has plateaued near 52% for three quarters, suggesting scale benefits are not yet fully realized.

The gross margin trajectory shows clear improvement from the 41% level two years ago, but the recent plateau indicates that the high-fixed-cost manufacturing model requires higher utilization to push toward the 60%+ levels of mature peers. Operating margin remains deeply negative at -30.6%, with SG&A consuming 68% of revenue, implying that overhead is scaling with revenue rather than providing operating leverage. The net margin of -29.6% in 2026Q3, excluding the one-time positive quarter in 2025Q3, underscores that the company is still far from profitability.

Returns on Capital Remain Deeply Negative

ROIC has hovered between -5.4% and -17.9% over the past ten quarters, as per reported figures, with no clear trend toward improvement, indicating that the company is not yet generating returns above its cost of capital.

Despite revenue growth, ROIC remains deeply negative, with the latest quarter at -6.4%. The improvement from the -17.9% trough in 2024Q3 is largely due to a one-time gain in 2025Q3 and a slightly larger asset base, not operational efficiency. ROE and ROA follow a similar pattern, with ROE at -7.8% in 2026Q3, reflecting the persistent net losses. The lack of positive returns suggests that the capital invested in the Factory of the Future and R&D is not yet yielding returns, and investors should monitor whether utilization gains can eventually drive ROIC toward positive territory.

Working Capital Cycle Lengthens

Cash conversion cycle extended to 80 days in 2026Q3 from 74 days a year earlier, as per financial statements, driven by a rise in DSO to 50 days and DIO to 56 days, indicating slower cash recovery.

The CCC has been relatively stable around 80 days over the past year, but it remains elevated compared to the 71 days seen in 2025Q2. DSO has increased from 43 to 50 days, suggesting that customers are taking longer to pay, possibly due to a shift in product mix or customer base. DIO has also risen from 43 to 56 days, reflecting higher inventory levels as the company scales production. DPO has improved from 15 to 26 days, indicating that Twist is taking longer to pay suppliers, which may be a deliberate cash management strategy but could strain supplier relationships if extended further.

Minimal Debt but Rising Dependence

Debt-to-equity rose to 0.21 in 2026Q3 from 0.16 in 2024Q2, as reported in SEC filings, though absolute debt remains modest at $93.6M, suggesting a manageable but increasing reliance on borrowings.

Twist's leverage is low in absolute terms, with a D/E of 0.21, but the trend is upward as the company's equity base erodes due to losses. Interest coverage is not calculable for recent quarters due to missing data, but the negative operating income suggests that interest expense, while small, is not covered by operating profits. The company's cash position of $117.4M provides a cushion, but with a net margin of -20.63%, the current cash burn rate implies a limited runway unless the company raises additional capital or achieves profitability sooner than expected.

Liquidity Buffer Thins Rapidly

Current ratio fell to 2.67 in 2026Q3 from 5.51 in 2024Q2, as per balance sheet data, while cash dropped from $243.3M to $117.4M, indicating a shrinking cushion against operational shocks.

The current ratio remains above 2, which is generally considered healthy, but the rapid decline from 5.51 to 2.67 over two years signals that the liquidity buffer is being consumed. The quick ratio of 2.38 suggests that inventory is not a major liquidity concern, but the trend is concerning. With negative free cash flow and a net loss of $35.1M in 2026Q3, the company's ability to weather a prolonged downturn or a delay in achieving profitability is diminishing. Investors should monitor the cash runway closely, as the current burn rate implies a need for additional financing within the next few quarters.

P/S Multiple Misleads on Value

The price-to-sales ratio of 19.13, as reported in valuation data, is often applied to Twist, but it obscures the company's negative margins and high cash burn, making EV/Sales a more appropriate metric.

Twist's P/S ratio of 19.13 appears rich, but it is not directly comparable to profitable peers like Illumina, which trades at a lower multiple. The market often values pre-profit companies on revenue multiples, but this can overstate value if the company's path to profitability is uncertain. A more appropriate metric would be EV/Sales, which accounts for the company's debt and cash position, but even that must be considered alongside the negative operating margin and the need for significant scale to achieve profitability. Investors should focus on the company's ability to convert revenue growth into gross margin expansion and eventually operating leverage, rather than relying solely on P/S.

Download Financial Ratios Data

Includes 30+ ratios · 10 years · Updated daily

Consensus & Technical Research Suite
Open TWST Terminal

TWST Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TWST — Frequently Asked Questions

Quick answers to the most common questions about buying TWST stock.

What is Twist Bioscience Corporation's P/E ratio?

Twist Bioscience Corporation's current P/E ratio is -126.6x. This places it at the 50th percentile of its historical range.

What is Twist Bioscience Corporation's ROE?

Twist Bioscience Corporation's return on equity (ROE) is -16.4%. The historical average is -39.5%.

Is TWST stock overvalued?

Based on historical data, Twist Bioscience Corporation is trading at a P/E of -126.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Twist Bioscience Corporation's profit margins?

Twist Bioscience Corporation has 50.7% gross margin and -36.2% operating margin.